Related Experiment Videos

Alendronate disturbs vesicular trafficking in osteoclasts

A Alakangas1, K Selander, M Mulari

  • 1Institute of Biomedicine, Department of Anatomy, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.

Insights

Alendronate, a bisphosphonate drug, stops bone breakdown by disrupting osteoclast vesicle transport. This impairs osteoclast function, leading to reduced bone resorption without decreasing osteoclast numbers.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Nitrogen-containing bisphosphonates like alendronate inhibit bone resorption.
  • Alendronate targets the mevalonate pathway, affecting protein prenylation and small GTPase function in osteoclasts.

Purpose of the Study:

  • To investigate alendronate's interference with vesicle transport in isolated rat osteoclasts.
  • To elucidate the cellular mechanisms underlying alendronate's inhibition of bone resorption.

Main Methods:

  • Isolated rat osteoclasts were treated with alendronate.
  • Bone resorption was assessed on alendronate-coated bone slices.
  • Ultrastructural changes in osteoclasts were examined using electron microscopy.

Main Results:

  • Alendronate treatment led to the accumulation of tartrate-resistant acid phosphatase- and electron-dense material-containing tubular vesicles.
  • Osteoclast changes included widened sealing zones, disorganized attachments, and incomplete ruffled borders.
  • Bone resorption was inhibited, with dissolution limited to pit edges, and osteoclast numbers remained unchanged.

Conclusions:

  • Alendronate inactivates osteoclasts by impairing intracellular vesicle transport.
  • Apoptosis is a secondary effect, not the primary mechanism of alendronate-induced osteoclast inactivation.

Related Concept Videos